TransMedics

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, TransMedics sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).

23 total trials 4 currently recruiting 13 completed top decile by trial count

TransMedics: 23 sponsored US clinical trials, 4 recruiting.

TransMedics sponsors 23 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 13 completed. The most-studied condition in this pipeline is Heart Transplant, with 6 trials.

Top-decile sponsor footprint

TransMedics ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 56/100

13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

23 total, page 1 of 1

RECRUITING NA

Enhancing Heart Allograft Function With the OCS Heart System Trial

NCT07145515

RECRUITING

US National TOP Registry

NCT06513091

RECRUITING

US National OCS Heart Perfusion (OHP) Registry

NCT05915299

RECRUITING

US National OCS Liver Perfusion (OLP) Registry

NCT05940857

ACTIVE NOT RECRUITING

OCS Liver Perfusion (OLP) Post-Approval Registry

NCT05074160

ACTIVE NOT RECRUITING

OCS Heart Perfusion Post-Approval Registry

NCT05047068

ACTIVE NOT RECRUITING

OCS DCD Heart + CAP Continued Follow-Up

NCT05741723

ACTIVE NOT RECRUITING

OCS™ Lung TOP Registry For Donor Lungs for Transplantation

NCT03639025

COMPLETED NA

Donor After Circulatory Death Heart CAP Trial

NCT04615182

TERMINATED NA

OCS Liver DCD Trial

NCT04194437

COMPLETED

OCS Liver PROTECT Continued Access Protocol (CAP) Continuation Post-Approval Study

NCT05096754

COMPLETED NA

OCS Liver PROTECT Continued Access Protocol

NCT04186221

COMPLETED NA

Donors After Circulatory Death Heart Trial

NCT03831048

COMPLETED

INSPIRE Continuation Post-Approval Study

NCT03868904

COMPLETED NA

Heart EXPAND Continued Access Protocol

NCT03835754

COMPLETED

OCS Lung Expand Post-Approval Study - Expand Follow-Up Data Collection

NCT04194398

TERMINATED NA

OCS Lung System EXPAND II Trial

NCT03343535

COMPLETED NA

OCS Liver PROTECT Trial: Preserving and Assessing Donor Livers for Transplantation

NCT02522871

COMPLETED

OCS Liver PROTECT Continuation Post-Approval Study

NCT05096741

COMPLETED NA

International EXPAND Heart Pivotal Trial

NCT02323321

COMPLETED NA

International EXPAND Lung Pivotal Trial

NCT01963780

COMPLETED NA

International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation

NCT01630434

COMPLETED NA

Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation

NCT00855712

What is open in the TransMedics pipeline

4 recruiting of 23 indexed (17% open); 13 completed (57%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Heart Transplant (6 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

TransMedics: open-pipeline peers nationwide

Peers matched on 23 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

TransMedics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 0%5%10%15%20%25% Total trials Recruiting share TransMedicsAMAG PharmaceuticalsAtriCureCara TherapeuticsCraig L Slingluff, JrImmunityBioOld Dominion UniversityTexas Tech UniversityMemorial Sloan Kettering Cancer Center
TransMedics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

TransMedics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 23 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this TransMedics page

23 registered trials is a research-attention snapshot, not an endorsement of TransMedics or any single study.

  • 4 of TransMedics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Heart Transplant is the condition TransMedics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heart Transplant trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

TransMedics pipeline card: 23 registered trials from official public datasets.Report a data error.